A new observational study published in Drug and Alcohol Dependence (Martins et al., 2026) exposes a stark treatment gap: among 2,926 pregnancies (0.3% of 909,241 total) with commercial insurance where women aged 15-54 received an OUD diagnosis between 2016 and 2020, only 40.2% received medication for opioid use disorder (MOUD). This retrospective claims-based analysis, while robust in its national scope for the commercially insured population, is limited by its observational design, potential coding inaccuracies in administrative data, and lack of disclosed conflicts of interest. With a focused OUD subsample of n=2,926, it identifies key associations—younger age and non-metropolitan residence linked to higher diagnosis rates, while co-occurring chronic pain or other substance use disorders predicted lower MOUD uptake, and multiple mental health conditions correlated with increased receipt.

The original MedicalXpress coverage accurately reports these figures but stops short of contextualizing the human and systemic costs or connecting this gap to broader patterns in the evolving opioid epidemic. What it misses is how this under-treatment directly fuels adverse maternal and infant outcomes. Untreated OUD elevates risks of preterm birth, placental abruption, stillbirth, and severe neonatal abstinence syndrome (NAS)—conditions that MOUD like buprenorphine or methadone can meaningfully mitigate, per established evidence. A landmark 2021 analysis in JAMA Pediatrics (Hirai et al.) drawing on CDC data documented a tripling of NAS incidence from 2010-2017, with maternal OUD diagnoses rising in parallel; that study of over 6 million births highlighted that Medicaid-covered populations—excluded from the Martins analysis—experience rates up to four times higher than commercially insured women, suggesting the true national gap may be even wider.

Synthesizing these with the American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 711 (2017, reaffirmed 2023), which designates MOUD as the gold standard based on decades of safety data from RCTs and cohort studies, reveals persistent systemic failures the Martins paper only hints at. Despite clear clinical guidelines, integration of addiction treatment into prenatal care remains fragmented. Rural and non-metropolitan areas, already flagged in the study for higher diagnosis prevalence, face acute shortages of waivered prescribers—a barrier only partially eased by the 2023 elimination of the X-waiver. Stigma, fear of child protective services involvement, and inadequate cross-training for obstetricians compound the problem. The positive link between multiple mental health disorders and MOUD receipt likely reflects greater healthcare system contact rather than better care coordination, exposing how siloed services fail women with complex needs.

This gap is not new but reflects deeper patterns: post-2016 surges in synthetic opioids coincided with rising maternal overdose deaths, now a leading cause of pregnancy-associated mortality per CDC data. The Martins findings underscore missed opportunities for intervention during a uniquely motivating life stage—pregnancy—when women often engage more with healthcare. Yet commercial insurance barriers, prior authorization requirements, and provider reluctance persist. Genuine progress demands structural solutions: co-located prenatal-MOUD clinics, universal screening without punitive reporting, expanded rural telehealth, and public-private efforts targeting the two-thirds of affected women the study implies are falling through the cracks. Without these, the opioid crisis will continue exacting an intergenerational toll, with infants facing NAS-related NICU stays and long-term neurodevelopmental risks, and mothers trapped in cycles of untreated addiction. The evidence is unequivocal; the inaction is the scandal.